Recursion Pharmaceuticals Inc vs SailPoint Inc. Common Stock — how do they compare? Recursion Pharmaceuticals Inc trades at $3.67 (market cap $2.08B), while SailPoint Inc. Common Stock trades at $19.03 (market cap $11.06B). The key difference: SailPoint Inc. Common Stock is far larger — about 5.3× Recursion Pharmaceuticals Inc's market cap, and SailPoint Inc. Common Stock is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and SailPoint Inc. Common Stock for 0 Days on average.
| RXRX | SAIL | |
|---|---|---|
Market Cap | $2.08B | $11.06B |
Volume | 19,700,033 | 3,269,663 |
Sector | Health | Technology |
52-Week High | $6.79 | $22.85 |
52-Week Low | $2.84 | $10.49 |
Typical Hold Time | 22 Days | 0 Days |
Enterprise Value | $1.60B | $10.76B |
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.835, down 4.36% today, with technical indicators showing a bullish trend despite recent weakness. The company reported revenue of $74.26M in 2025 but posted a significant net loss of -$644.76M, reflecting negative profit margins. Recent news highlights strategic AI partnerships and pipeline expansion, though the stock faces high short interest and ongoing operational losses.
Outlook remains speculative with 40% analyst buy ratings but substantial financial losses. Key opportunities include AI-driven drug discovery partnerships, while risks involve cash burn, competitive pressures, and delayed profitability. The stock's valuation at 36.1x sales appears stretched given current financial performance.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →SailPoint, Inc. develops identity security software that helps enterprises manage and govern access to applications and data across users, machines, and AI agents. Its unified identity security platform combines automation and intelligence to control identity-related risk at scale for large organizations.
Read more on SAIL →